**Core Concept**
The question is testing the understanding of the pharmacological mechanism of action of drugs used in the treatment of osteoporosis. Specifically, it requires knowledge of the role of RANKL and osteoclasts in bone resorption and how certain drugs target this pathway.

**Why the Correct Answer is Right**
Denosumab is a human monoclonal antibody that targets RANKL, a protein essential for the formation, function, and survival of osteoclasts. By binding to RANKL, denosumab prevents its interaction with its receptor, RANK, on the surface of osteoclasts and their precursors, leading to a decrease in osteoclast activity and subsequent reduction in bone resorption. This mechanism of action is distinct from other osteoporosis treatments that work by either inhibiting osteoclast activity directly (e.g., bisphosphonates like alendronate) or promoting osteoblast activity (e.g., teriparatide).

**Why Each Wrong Option is Incorrect**
**Option A:** Teriparatide is a recombinant form of parathyroid hormone that works by stimulating osteoblast activity and increasing bone formation, which is opposite to the mechanism of action of denosumab.
**Option B:** Alendronate is a bisphosphonate that inhibits osteoclast activity by binding to hydroxyapatite in bone and interfering with the mevalonate pathway, which is a different mechanism of action from denosumab.
**Option D:** Estrogen is a hormone that plays a role in maintaining bone health, particularly in premenopausal women, but it does not directly target RANKL or osteoclasts like denosumab.

**Clinical Pearl / High-Yield Fact**
Denosumab is a useful option for patients with osteoporosis who have had fractures or are at high risk of fracture, particularly those with a history of glucocorticoid use or those with Paget's disease.

**✓ Correct Answer: C. Denosumab**